Harrow Announces Second-Quarter 2025 Financial Results
Harrow (NASDAQ: HROW), a leading ophthalmic solutions provider, reported strong Q2 2025 financial results with total revenues of $63.7 million, up 30% year-over-year. The company achieved GAAP net income of $5.0 million and Adjusted EBITDA of $17.0 million.
Key highlights include VEVYE®'s 66% sequential prescription growth with 50,000 new prescriptions and a 3% market share gain. The company secured exclusive U.S. rights to Samsung Bioepis' ophthalmology biosimilars (BYOOVIZ® and OPUVIZ™) and acquired BYQLOVI™ for post-operative inflammation treatment. Harrow maintains its forecast of over $280 million in revenue for 2025, with strong cash position of $53.0 million.
The company expanded its VEVYE® Access for All program through a strategic alliance with Apollo Care, adding 500+ pharmacies nationwide.Harrow (NASDAQ: HROW), fornitore leader di soluzioni oftalmiche, ha registrato solidi risultati finanziari del 2° trimestre 2025 con ricavi totali di $63.7 million, in aumento del 30% su base annua. La società ha conseguito un utile netto GAAP di $5.0 million e un Adjusted EBITDA di $17.0 million.
I punti salienti includono la crescita sequenziale delle prescrizioni di VEVYE® del 66%, con 50.000 nuove prescrizioni e un guadagno della quota di mercato del 3%. L'azienda ha ottenuto i diritti esclusivi per gli Stati Uniti sui biosimilari oftalmici di Samsung Bioepis (BYOOVIZ® e OPUVIZ™) e ha acquisito BYQLOVI™ per il trattamento dell'infiammazione post-operatoria. Harrow mantiene la previsione di oltre $280 million in revenue for 2025 e dispone di una solida posizione di cassa pari a $53.0 million.
La società ha inoltre ampliato il programma VEVYE® Access for All tramite un'alleanza strategica con Apollo Care, aggiungendo oltre 500 farmacie su scala nazionale.
Harrow (NASDAQ: HROW), proveedor líder de soluciones oftálmicas, informó sólidos resultados financieros del 2T 2025 con ingresos totales de $63.7 million, un aumento del 30% interanual. La compañía registró un resultado neto GAAP de $5.0 million y un Adjusted EBITDA de $17.0 million.
Entre los puntos destacados figura el crecimiento secuencial de prescripciones de VEVYE® del 66%, con 50,000 nuevas prescripciones y una ganancia de cuota de mercado del 3%. La empresa aseguró los derechos exclusivos en EE. UU. de los biosimilares oftálmicos de Samsung Bioepis (BYOOVIZ® y OPUVIZ™) y adquirió BYQLOVI™ para el tratamiento de la inflamación postoperatoria. Harrow mantiene su previsión de más de $280 million in revenue for 2025 y cuenta con una sólida posición de caja de $53.0 million.
La compañía amplió además su programa VEVYE® Access for All mediante una alianza estratégica con Apollo Care, incorporando más de 500 farmacias a nivel nacional.
Harrow (NASDAQ: HROW), 선도적인 안과 솔루션 제공업체는 총매출 $63.7 million로 전년 대비 30% 증가한 2025년 2분기 실적을 발표했습니다. 회사는 GAAP 기준 순이익 $5.0 million과 조정 EBITDA $17.0 million을 달성했습니다.
주요 내용으로는 VEVYE® 처방이 전분기 대비 66% 증가하여 50,000건의 신규 처방을 기록하고 시장점유율이 3%포인트 상승한 점이 있습니다. 회사는 삼성바이오에피스의 안과용 바이오시밀러(BYOOVIZ® 및 OPUVIZ™)에 대한 미국 내 독점권을 확보했으며, 수술 후 염증 치료제 BYQLOVI™를 인수했습니다. Harrow는 2025년 매출이 $280 million 이상일 것이라는 전망을 유지하고 있으며, 현금 잔고는 $53.0 million으로 견고합니다.
또한 회사는 Apollo Care와의 전략적 제휴를 통해 VEVYE® Access for All 프로그램을 확대하여 전국적으로 500개 이상의 약국을 추가했습니다.
Harrow (NASDAQ: HROW), fournisseur majeur de solutions ophtalmiques, a annoncé de solides résultats financiers du 2e trimestre 2025 avec des revenus totaux de $63.7 million, en hausse de 30% sur un an. La société a réalisé un résultat net GAAP de $5.0 million et un EBITDA ajusté de $17.0 million.
Parmi les points marquants, VEVYE® affiche une croissance séquentielle des prescriptions de 66%, avec 50 000 nouvelles prescriptions et un gain de part de marché de 3%. L'entreprise a obtenu les droits exclusifs aux États-Unis pour les biosimilaires ophtalmiques de Samsung Bioepis (BYOOVIZ® et OPUVIZ™) et a acquis BYQLOVI™ pour le traitement de l'inflammation post-opératoire. Harrow maintient ses prévisions de plus de $280 million in revenue for 2025 et dispose d'une trésorerie solide de $53.0 million.
La société a par ailleurs étendu son programme VEVYE® Access for All via une alliance stratégique avec Apollo Care, ajoutant plus de 500 pharmacies à l'échelle nationale.
Harrow (NASDAQ: HROW), ein führender Anbieter ophthalmischer Lösungen, meldete starke Finanzergebnisse für Q2 2025 mit einem Gesamtumsatz von $63.7 million, ein Plus von 30% im Jahresvergleich. Das Unternehmen erzielte ein GAAP-Nettogewinn von $5.0 million sowie ein Adjusted EBITDA von $17.0 million.
Zu den Highlights zählt ein sequenzielles Rezeptwachstum von VEVYE® um 66% mit 50.000 neuen Rezepten und einem Marktanteilsgewinn von 3%. Das Unternehmen sicherte sich die exklusiven US-Rechte an den ophthalmologischen Biosimilars von Samsung Bioepis (BYOOVIZ® und OPUVIZ™) und erwarb BYQLOVI™ zur Behandlung postoperativer Entzündungen. Harrow bestätigt seine Prognose von mehr als $280 million in revenue for 2025 und verfügt über eine starke Barposition von $53.0 million.
Zudem hat das Unternehmen das VEVYE® Access for All-Programm durch eine strategische Partnerschaft mit Apollo Care ausgeweitet und über 500 Apotheken landesweit hinzugefügt.
- Revenue increased 30% YoY to $63.7 million
- Achieved GAAP net income of $5.0 million, compared to prior-year loss
- Adjusted EBITDA nearly doubled to $17.0 million
- VEVYE® prescriptions grew 66% sequentially with 3% market share gain
- Secured exclusive U.S. rights to Samsung Bioepis' ophthalmology portfolio
- Expanded pharmacy network to 500+ locations through Apollo Care partnership
- Gross margin improved to 75% from 74% year-over-year
- Core net loss of $4.3 million for the six-month period
- Basic EPS loss of $0.35 for the six-month period
Insights
Harrow delivers strong Q2 with 30% revenue growth, positive net income, and significant product momentum across portfolio.
Harrow's Q2 2025 financial performance demonstrates a significant inflection point toward profitability and scale. Revenue of
The company's cash position of
VEVYE's performance is particularly noteworthy with
The company's product diversification strategy is showing results with IHEEZO gaining momentum and TRIESENCE volumes improving. The recent acquisition of exclusive U.S. rights to Samsung Bioepis' ophthalmology biosimilars (BYOOVIZ and OPUVIZ) and BYQLOVI represent significant growth opportunities with minimal incremental costs, potentially creating substantial operating leverage.
The transition to profitability is evident in both GAAP metrics (
Second-Quarter 2025 and Recent Selected Highlights:
- Total revenues of
$63.7 million , a30% increase over$48.9 million recorded in the prior-year period - GAAP net income of
$5.0 million - Adjusted EBITDA of
$17.0 million - Cash and cash equivalents of
$53.0 million as of June 30, 2025
A Media Snippet accompanying this announcement is available by clicking on this link.
NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for the business.
“The second quarter provided a strong financial and operational foundation for the back half of the year,” said Mark L. Baum, Chief Executive Officer of Harrow. “These results have positioned us to strengthen our capital base and are a proof point as to the financial leverage we believe our business has. We remain on track to deliver greater than
“VEVYE® continues to gain commercial momentum, adding nearly
“In addition, IHEEZO® has found its growth footing and is expected to deliver record performance through the balance of the year. TRIESENCE® volumes are improving, and with a coming launch in its largest market, ocular inflammation, we expect to finally demonstrate a revenue trajectory consistent with our original acquisition thesis – that TRIESENCE should eventually deliver
“In sum, our commercial platform is firing on all cylinders – scaling rapidly and driving strong, growing profitability as demand surges for VEVYE and IHEEZO, and improves the rest of our portfolio. With powerful new revenue streams on deck – including the Samsung biosimilars portfolio, BYQLOVI™, and the expansion of TRIESENCE into its largest potential market – all with minimal incremental cost, we are poised to unlock additional operational leverage and deliver meaningful profitability for Harrow stockholders.”
Business Highlights:
- Apollo Care Strategic Alliance for VAFA
- Harrow recently entered into a strategic alliance with Apollo Care, an innovative service provider for patient access and commercial solutions, as Harrow’s second specialty pharmacy partner for the VAFA program. With 500+ pharmacies and full nationwide coverage, Apollo Care’s pharmacy network is broadly contracted with major and small commercial, TRICARE and Medicare plans, positioning it to accelerate VAFA’s expansion while driving broader insurance coverage.
- Samsung Bioepis
- In July 2025, Harrow secured the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEA (aflibercept) — two of the most widely used anti-VEGF therapies for retinal diseases.
- BYQLOVI Acquisition
- In June 2025, Harrow acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension)
0.05% . BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years.
- In June 2025, Harrow acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension)
Second Quarter 2025 Financial Results:
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Total revenues | $ | 63,742,000 | $ | 48,939,000 | $ | 111,573,000 | $ | 83,526,000 | |||||||
| Gross margin | |||||||||||||||
| Core gross margin(1) | |||||||||||||||
| Net income (loss) | 4,995,000 | (6,473,000 | ) | (12,785,000 | ) | (20,038,000 | ) | ||||||||
| Core net income (loss)(1) | 9,227,000 | (2,047,000 | ) | (4,327,000 | ) | (11,836,000 | ) | ||||||||
| Adjusted EBITDA(1) | 17,006,000 | 8,803,000 | 15,021,000 | 9,030,000 | |||||||||||
| Net income (loss) per share: | |||||||||||||||
| Basic | 0.14 | (0.18 | ) | (0.35 | ) | (0.56 | ) | ||||||||
| Diluted | 0.13 | (0.18 | ) | (0.35 | ) | (0.56 | ) | ||||||||
| Core net income (loss) per share:(1) | |||||||||||||||
| Basic | 0.25 | (0.06 | ) | (0.12 | ) | (0.33 | ) | ||||||||
| Diluted | 0.24 | (0.06 | ) | (0.12 | ) | (0.33 | ) | ||||||||
(1) Core gross margin, core net income (loss), core basic and diluted net income (loss) per share (collectively, “Core Results”), and Adjusted EBITDA are non-GAAP measures. For additional information, including a reconciliation of such Core Results and Adjusted EBITDA to the most directly comparable measures presented in accordance with GAAP, see the explanation of non-GAAP measures and reconciliation tables at the end of this release.
Conference Call and Webcast
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward--looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, refinance and otherwise service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking- statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking- statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Contact:
Mike Biega, VP of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890
| HARROW, INC. CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| June 30, 2025 | December 31, 2024 | ||||||
| (unaudited) | |||||||
| ASSETS | |||||||
| Cash and cash equivalents | $ | 52,963,000 | $ | 47,247,000 | |||
| All other current assets | 101,927,000 | 142,404,000 | |||||
| Total current assets | 154,890,000 | 189,651,000 | |||||
| All other assets | 190,143,000 | 199,320,000 | |||||
| TOTAL ASSETS | $ | 345,033,000 | $ | 388,971,000 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities | $ | 248,884,000 | $ | 91,343,000 | |||
| Loans payable, net of unamortized debt discount and current portion | 38,484,000 | 219,539,000 | |||||
| All other liabilities | 8,366,000 | 8,792,000 | |||||
| TOTAL LIABILITIES | 295,734,000 | 319,674,000 | |||||
| TOTAL STOCKHOLDERS' EQUITY | 49,299,000 | 69,297,000 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 345,033,000 | $ | 388,971,000 | |||
| HARROW, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Total revenues | $ | 63,742,000 | $ | 48,939,000 | $ | 111,573,000 | $ | 83,526,000 | |||||||
| Cost of sales | 16,230,000 | 12,539,000 | 31,754,000 | 23,092,000 | |||||||||||
| Gross profit | 47,512,000 | 36,400,000 | 79,819,000 | 60,434,000 | |||||||||||
| Selling, general and administrative | 33,235,000 | 31,817,000 | 73,748,000 | 60,630,000 | |||||||||||
| Research and development | 2,868,000 | 3,053,000 | 5,894,000 | 5,202,000 | |||||||||||
| Total operating expenses | 36,103,000 | 34,870,000 | 79,642,000 | 65,832,000 | |||||||||||
| Income (loss) from operations | 11,409,000 | 1,530,000 | 177,000 | (5,398,000 | ) | ||||||||||
| Total other expense, net | (6,414,000 | ) | (7,348,000 | ) | (12,962,000 | ) | (13,985,000 | ) | |||||||
| Income tax expense | - | 655,000 | - | 655,000 | |||||||||||
| Net income (loss) attributable to Harrow, Inc. | $ | 4,995,000 | $ | (6,473,000 | ) | $ | (12,785,000 | ) | $ | (20,038,000 | ) | ||||
| Net income (loss) per share: | |||||||||||||||
| Basic | $ | 0.14 | $ | (0.18 | ) | $ | (0.35 | ) | $ | (0.56 | ) | ||||
| Diluted | $ | 0.13 | $ | (0.18 | ) | $ | (0.35 | ) | $ | (0.56 | ) | ||||
| HARROW, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| For the Six Months Ended June 30, | |||||||
| 2025 | 2024 | ||||||
| Net cash provided by (used in): | |||||||
| Operating activities | $ | 18,865,000 | $ | (7,374,000 | ) | ||
| Investing activities | (505,000 | ) | 4,993,000 | ||||
| Financing activities | (12,644,000 | ) | (736,000 | ) | |||
| Net change in cash and cash equivalents | 5,716,000 | (3,117,000 | ) | ||||
| Cash and cash equivalents at beginning of the period | 47,247,000 | 74,085,000 | |||||
| Cash and cash equivalents at end of the period | $ | 52,963,000 | $ | 70,968,000 | |||
Non-GAAP Financial Measures
In addition to the Company’s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA and Core Results, unaudited financial measures that are not calculated in accordance with GAAP, to evaluate the Company’s financial results and performance and to plan and forecast future periods. Adjusted EBITDA and Core Results are considered “non-GAAP” financial measures within the meaning of Regulation G promulgated by the SEC. Management believes that these non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, provide a more complete understanding of the Company’s results of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA and Core Results provide meaningful supplemental information regarding the Company’s performance because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) they exclude the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance; and (iii) they are used by institutional investors and the analyst community to help analyze the Company’s results. However, Adjusted EBITDA, Core Results, and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company’s competitors.
Adjusted EBITDA
The Company defines Adjusted EBITDA as net income (loss), excluding the effects of stock-based compensation and expenses, interest, taxes, depreciation, amortization, investment loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss) as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.
The following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net income (loss), for the three months and six months ended June 30, 2025 and for the same period in 2024:
| HARROW, INC. RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA | |||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| GAAP net income (loss) | $ | 4,995,000 | $ | (6,473,000 | ) | $ | (12,785,000 | ) | $ | (20,038,000 | ) | ||||
| Stock-based compensation and expenses | 875,000 | 4,271,000 | 5,431,000 | 8,440,000 | |||||||||||
| Interest expense, net | 6,408,000 | 5,471,000 | 12,956,000 | 10,886,000 | |||||||||||
| Income tax expense | - | 655,000 | - | 655,000 | |||||||||||
| Depreciation | 496,000 | 453,000 | 961,000 | 885,000 | |||||||||||
| Amortization of intangible assets | 4,226,000 | 2,549,000 | 8,452,000 | 5,103,000 | |||||||||||
| Investment loss, net | - | 1,923,000 | - | 3,171,000 | |||||||||||
| Other expense (income), net | 6,000 | (46,000 | ) | 6,000 | (72,000 | ) | |||||||||
| Adjusted EBITDA | $ | 17,006,000 | $ | 8,803,000 | $ | 15,021,000 | $ | 9,030,000 | |||||||
Core Results
Harrow Core Results, including core gross margin, core net income (loss), and core basic and diluted income (loss) per share exclude (1) all amortization and impairment charges of intangible assets, excluding software development costs, (2) net gains and losses on investments and equity securities, including equity method gains and losses and equity valued at fair value through profit and loss (FVPL), and preferred stock dividends, and (3) gains/losses on forgiveness of debt. In certain periods, Core Results may also exclude fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, obligations related to product recalls, certain acquisition-related items, restructuring charges/releases and associated items, related legal items, gains/losses on early extinguishment of debt or debt modifications, impairments of property, plant and equipment and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a
The following is a reconciliation of Core Results, non-GAAP measures, to the most comparable GAAP measures for the three months and six months ended June 30, 2025 and 2024:
| For the Three Months Ended June 30, 2025 | ||||||||||||||||||||
| GAAP Results | Amortization of Certain Intangible Assets | Investment Gains (Losses) | Other Items | Core Results | ||||||||||||||||
| Gross profit | $ | 47,512,000 | $ | 3,780,000 | $ | - | $ | - | $ | 51,292,000 | ||||||||||
| Gross margin | 75 | % | 80 | % | ||||||||||||||||
| Operating income | 11,409,000 | 4,226,000 | - | - | 15,635,000 | |||||||||||||||
| Income before taxes | 4,995,000 | 4,226,000 | - | 6,000 | 9,227,000 | |||||||||||||||
| Taxes | - | - | - | - | - | |||||||||||||||
| Net income | 4,995,000 | 4,226,000 | - | 6,000 | 9,227,000 | |||||||||||||||
| Income per share ($)(1): | ||||||||||||||||||||
| Basic | 0.14 | 0.25 | ||||||||||||||||||
| Diluted | 0.13 | 0.24 | ||||||||||||||||||
| Weighted average number of shares of common stock outstanding: | ||||||||||||||||||||
| Basic | 36,790,306 | 36,790,306 | ||||||||||||||||||
| Diluted | 38,853,855 | 38,853,855 | ||||||||||||||||||
| For the Six Months Ended June 30, 2025 | ||||||||||||||||||||
| GAAP Results | Amortization of Certain Intangible Assets | Investment Gains (Losses) | Other Items | Core Results | ||||||||||||||||
| Gross profit | $ | 79,819,000 | $ | 7,560,000 | $ | - | $ | - | $ | 87,379,000 | ||||||||||
| Gross margin | 72 | % | 78 | % | ||||||||||||||||
| Operating income | 177,000 | 8,452,000 | - | - | 8,629,000 | |||||||||||||||
| Loss before taxes | (12,785,000 | ) | 8,452,000 | 6,000 | (4,327,000 | ) | ||||||||||||||
| Taxes | - | - | - | - | - | |||||||||||||||
| Net loss | (12,785,000 | ) | 8,452,000 | - | 6,000 | (4,327,000 | ) | |||||||||||||
| Basic and diluted loss per share ($)(1) | (0.35 | ) | (0.12 | ) | ||||||||||||||||
| Weighted average number of shares of common stock outstanding, basic and diluted | 36,304,787 | 36,304,787 | ||||||||||||||||||
| For the Three Months Ended June 30, 2024 | |||||||||||||||||||
| GAAP Results | Amortization of Certain Intangible Assets | Investment Gains (Losses) | Other Items | Core Results | |||||||||||||||
| Gross profit | $ | 36,400,000 | $ | 2,140,000 | $ | - | $ | - | $ | 38,540,000 | |||||||||
| Gross margin | 74 | % | 79 | % | |||||||||||||||
| Operating income | 1,530,000 | 2,549,000 | - | - | 4,079,000 | ||||||||||||||
| (Loss) income before taxes | (5,818,000 | ) | 2,549,000 | 1,923,000 | (46,000 | ) | (1,392,000 | ) | |||||||||||
| Taxes | (655,000 | ) | - | - | - | (655,000 | ) | ||||||||||||
| Net (loss) income | (6,473,000 | ) | 2,549,000 | 1,923,000 | (46,000 | ) | (2,047,000 | ) | |||||||||||
| Basic and diluted loss per share ($)(1) | (0.18 | ) | (0.06 | ) | |||||||||||||||
| Weighted average number of shares of common stock outstanding, basic and diluted | 35,618,977 | 35,618,977 | |||||||||||||||||
| For the Six Months Ended June 30, 2024 | |||||||||||||||||||
| GAAP Results | Amortization of Certain Intangible Assets | Investment Gains (Losses) | Other Items | Core Results | |||||||||||||||
| Gross profit | $ | 60,434,000 | $ | 4,280,000 | $ | - | $ | - | $ | 64,714,000 | |||||||||
| Gross margin | 72 | % | 78 | % | |||||||||||||||
| Operating loss | (5,398,000 | ) | 5,103,000 | - | - | (295,000 | ) | ||||||||||||
| (Loss) income before taxes | (19,383,000 | ) | 5,103,000 | 3,171,000 | (72,000 | ) | (11,181,000 | ) | |||||||||||
| Taxes | (655,000 | ) | - | - | - | (655,000 | ) | ||||||||||||
| Net (loss) income | (20,038,000 | ) | 5,103,000 | 3,171,000 | (72,000 | ) | (11,836,000 | ) | |||||||||||
| Basic and diluted loss per share ($)(1) | (0.56 | ) | (0.33 | ) | |||||||||||||||
| Weighted average number of shares of common stock outstanding, basic and diluted | 35,544,312 | 35,544,312 | |||||||||||||||||
(1) Core basic and diluted loss per share is calculated using the weighted-average number of shares of common stock outstanding during the period. Core basic and diluted loss per share also contemplates dilutive shares associated with equity based awards as described in Note 2 and elsewhere in the Consolidated Financial Statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
FAQ
What were Harrow's (HROW) Q2 2025 earnings results?
How is Harrow's VEVYE® performing in the market?
What new acquisitions did Harrow (HROW) announce in Q2 2025?
What is Harrow's revenue guidance for 2025?
How has Harrow expanded its VEVYE Access for All (VAFA) program?
